In the latest Health Policy Outlook, John E. Calfee makes the case for substantial social gains from preserving several years of data exclusivity for firms innovating new biotech drugs.

• Read this issue
• All Health Policy Outlooks
• AEI's Outlook series

Anupam B. Jena and Tomas J. Philipson argue that the use of cost-effectiveness analysis to curb health care spending may do more harm than good.

• Information and orders
• Download a free copy